US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6111166A
(en)
*
|
1994-09-19 |
2000-08-29 |
Medarex, Incorporated |
Transgenic mice expressing human Fcα and β receptors
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
CA2249354A1
(en)
*
|
1996-03-28 |
1997-10-02 |
Genitrix, L.L.C. |
Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
DE19725586C2
(de)
*
|
1997-06-17 |
1999-06-24 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
|
DE19735105A1
(de)
*
|
1997-08-13 |
1999-03-04 |
Univ Albert Ludwigs Freiburg |
Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
|
WO1999028349A2
(en)
|
1997-12-02 |
1999-06-10 |
Medarex, Inc. |
CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US7833528B2
(en)
*
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US7005498B1
(en)
*
|
1998-10-05 |
2006-02-28 |
Pharmexa A/S |
Methods for therapeutic vaccination
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
ES2282120T3
(es)
*
|
1999-06-25 |
2007-10-16 |
Genentech, Inc. |
Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
CA2382100A1
(en)
|
1999-08-27 |
2001-03-08 |
Genentech, Inc. |
Dosages for treatment with anti-erbb2 antibodies
|
DE19962583A1
(de)
*
|
1999-12-23 |
2001-06-28 |
Mueller Hermelink Hans Konrad |
Antikörper gegen Plasmazellen
|
WO2001048205A2
(en)
*
|
1999-12-29 |
2001-07-05 |
Corixa Corporation |
Murine neu sequences and methods of use therefor
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
KR101135233B1
(ko)
|
2000-05-19 |
2012-04-12 |
제넨테크, 인크. |
ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
AU2001265417A1
(en)
*
|
2000-06-05 |
2002-04-08 |
University Of Tennessee Corporation |
Compositions and methods for the endocytic presentation of immunosuppressive factors
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
DE10043437A1
(de)
*
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
CN1501928A
(zh)
|
2000-11-02 |
2004-06-02 |
斯隆-凯特林癌症研究所 |
结合hsp90的小分子组合物
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7265208B2
(en)
|
2001-05-01 |
2007-09-04 |
The Regents Of The University Of California |
Fusion molecules and treatment of IgE-mediated allergic diseases
|
PT2163256E
(pt)
|
2001-05-11 |
2015-11-20 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
JP2004529188A
(ja)
|
2001-05-23 |
2004-09-24 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
上昇に関連した癌の治療法
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
AU2002319402B2
(en)
*
|
2001-06-28 |
2008-09-11 |
Domantis Limited |
Dual-specific ligand and its use
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
GB0124670D0
(en)
*
|
2001-10-15 |
2001-12-05 |
Hewlett Packard Co |
Method and apparatus for encrypting data
|
GB0124681D0
(en)
*
|
2001-10-15 |
2001-12-05 |
Hewlett Packard Co |
Method and apparatus for encrypting data
|
GB0124686D0
(en)
|
2001-10-15 |
2001-12-05 |
Hewlett Packard Co |
A scheme for splitting trusted authorities based on the shamir's secret sharing
|
US7491690B2
(en)
*
|
2001-11-14 |
2009-02-17 |
Northwestern University |
Self-assembly and mineralization of peptide-amphiphile nanofibers
|
DE60232688D1
(de)
|
2001-11-20 |
2009-07-30 |
Univ Duke |
Grenzflächen-biomaterialien
|
ATE469167T1
(de)
|
2002-02-06 |
2010-06-15 |
Vicor Technologies Inc |
Anti-infarkt-moleküle
|
AU2003216436A1
(en)
|
2002-02-08 |
2003-09-02 |
Life Technologies Corporation |
Compositions and methods for restoring immune responsiveness in patients with immunological defects
|
WO2003070749A2
(en)
*
|
2002-02-15 |
2003-08-28 |
Northwestern University |
Self-assembly of peptide-amphiphile nanofibers under physiological conditions
|
US7053188B2
(en)
*
|
2002-02-22 |
2006-05-30 |
Purdue Research Foundation |
Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
|
EP1504034B1
(en)
|
2002-05-06 |
2012-12-12 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
AU2003244817B2
(en)
*
|
2002-06-28 |
2010-08-26 |
Domantis Limited |
Antigen-binding immunoglobulin single variable domains and dual-specific constructs
|
AU2003257181A1
(en)
|
2002-08-05 |
2004-02-23 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20050260213A1
(en)
*
|
2004-04-16 |
2005-11-24 |
Scott Koenig |
Fcgamma-RIIB-specific antibodies and methods of use thereof
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US7534761B1
(en)
|
2002-08-21 |
2009-05-19 |
North Western University |
Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
|
WO2004040000A2
(en)
*
|
2002-09-09 |
2004-05-13 |
Nura, Inc |
G protein coupled receptors and uses thereof
|
US20080260744A1
(en)
*
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US7148332B2
(en)
|
2002-09-11 |
2006-12-12 |
Spring Bioscience |
High affinity monoclonal antibody for recognizing the estrogen receptor (ER) and method for creating the antibody
|
EP1558650A2
(en)
*
|
2002-11-08 |
2005-08-03 |
Ablynx N.V. |
Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
|
CA2505325C
(en)
*
|
2002-11-08 |
2014-02-25 |
Ablynx N.V. |
Stabilized single domain antibodies
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
CN102584997A
(zh)
*
|
2002-11-08 |
2012-07-18 |
埃博灵克斯股份有限公司 |
针对肿瘤坏死因子-α的单结构域抗体及其用途
|
US7554021B2
(en)
*
|
2002-11-12 |
2009-06-30 |
Northwestern University |
Composition and method for self-assembly and mineralization of peptide amphiphiles
|
AU2003298647A1
(en)
*
|
2002-11-14 |
2004-06-15 |
Claussen, Randal, C. |
Synthesis and self-assembly of abc triblock bola peptide
|
WO2004048525A2
(en)
*
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
US7682688B2
(en)
*
|
2002-11-26 |
2010-03-23 |
University Of Utah Research Foundation |
Microporous materials, methods, and articles for localizing and quantifying analytes
|
US7597936B2
(en)
*
|
2002-11-26 |
2009-10-06 |
University Of Utah Research Foundation |
Method of producing a pigmented composite microporous material
|
WO2004053104A2
(en)
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
AU2003290330A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
AU2004204494B2
(en)
*
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1596813A4
(en)
*
|
2003-01-31 |
2008-02-20 |
Five Prime Therapeutics Inc |
POLYPEPTIDES EXPRESSED BY LUNGS
|
CA2515651A1
(en)
|
2003-02-11 |
2004-08-26 |
Northwestern University |
Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
|
WO2005018669A1
(en)
*
|
2003-08-18 |
2005-03-03 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
WO2005056576A2
(en)
|
2003-12-05 |
2005-06-23 |
Northwestern University |
Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
|
AU2004296181A1
(en)
|
2003-12-05 |
2005-06-23 |
Northwestern University |
Self-assembling peptide amphiphiles and related methods for growth factor delivery
|
WO2005069969A2
(en)
|
2004-01-21 |
2005-08-04 |
University Of Utah Research Foundation |
Mutant sodium channel nav1.7 and methods related thereto
|
WO2005110474A2
(en)
*
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2006030602A1
(ja)
*
|
2004-09-16 |
2006-03-23 |
Mitsubishi Pharma Corporation |
卵巣癌の診断および/または治療薬
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
US9403828B2
(en)
|
2005-02-01 |
2016-08-02 |
Sloan-Kettering Institute For Cancer Research |
Small-molecule Hsp90 inhibitors
|
US7834181B2
(en)
|
2005-02-01 |
2010-11-16 |
Slaon-Kettering Institute For Cancer Research |
Small-molecule Hsp90 inhibitors
|
CN101115836A
(zh)
*
|
2005-02-09 |
2008-01-30 |
健泰科生物技术公司 |
用基质金属蛋白酶拮抗剂抑制her2脱落
|
EP2548575A1
(en)
|
2005-02-15 |
2013-01-23 |
Duke University |
Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
|
ES2440481T3
(es)
*
|
2005-02-23 |
2014-01-29 |
Genentech, Inc. |
Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
|
NZ560649A
(en)
*
|
2005-03-04 |
2011-03-31 |
Univ Northwestern |
Angiogenic heparin binding peptide amphiphiles, peptide amphiphiles, self-assembled composition and related methods of use
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US7919104B2
(en)
|
2005-05-19 |
2011-04-05 |
The United States Of America As Represented By The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof
|
SI2163562T1
(sl)
|
2005-06-21 |
2014-01-31 |
Xoma (Us) Llc |
IL-1 beta vezavna protitelesa in njihovi fragmenti
|
CA3201163A1
(en)
|
2005-07-01 |
2007-01-11 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
WO2007014278A2
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals, Inc. |
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
PT1919503E
(pt)
|
2005-08-10 |
2015-01-05 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
WO2007063308A2
(en)
*
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
KR20080110987A
(ko)
*
|
2006-01-04 |
2008-12-22 |
메르크 파텐트 게엠베하 |
항-egfr 및 항-her2 항체를 이용하는 조합 요법
|
US8470965B2
(en)
*
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
EP1998792B1
(en)
*
|
2006-03-01 |
2015-02-18 |
The University of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
EP1999148B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
SG170110A1
(en)
*
|
2006-03-10 |
2011-04-29 |
Macrogenics Inc |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
JP5524610B2
(ja)
|
2006-04-07 |
2014-06-18 |
ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク |
トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
EP2021029B1
(en)
*
|
2006-05-26 |
2014-06-11 |
MacroGenics, Inc. |
Humanized fc gamma riib-specific antibodies and methods of use thereof
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
LT2029173T
(lt)
*
|
2006-06-26 |
2016-11-10 |
Macrogenics, Inc. |
Fc riib specifiniai antikūnai ir jų panaudojimo būdai
|
PT2066349E
(pt)
|
2006-09-08 |
2012-07-02 |
Medimmune Llc |
Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
US7492312B2
(en)
*
|
2006-11-14 |
2009-02-17 |
Fam Adly T |
Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
|
EA200970477A1
(ru)
|
2006-11-15 |
2009-12-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к btla и способы применения
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
EP2094306A2
(en)
|
2006-12-20 |
2009-09-02 |
XOMA Technology Ltd. |
Treatment of il-1-beta related diseases
|
JP2010514839A
(ja)
*
|
2007-01-03 |
2010-05-06 |
バーナム インスティテュート フォー メディカル リサーチ |
クロット結合化合物に関連する方法および組成物
|
CN110613845A
(zh)
|
2007-01-25 |
2019-12-27 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
CL2008000614A1
(es)
*
|
2007-03-02 |
2008-09-05 |
Genentech Inc F Hoffmann La Ro |
Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
US8076295B2
(en)
*
|
2007-04-17 |
2011-12-13 |
Nanotope, Inc. |
Peptide amphiphiles having improved solubility and methods of using same
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 icos 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
MX2020011303A
(es)
|
2007-05-14 |
2021-12-17 |
Astrazeneca Ab |
Metodos para reducir niveles de eosinofilos.
|
MX2009012676A
(es)
|
2007-05-23 |
2010-02-12 |
Uab Research Foundation |
Neuraminidasa neumococica no toxica y sus usos.
|
SG182170A1
(en)
|
2007-06-06 |
2012-07-30 |
Domantis Ltd |
Polypeptides, antibody variable domains and antagonists
|
SI2171090T1
(sl)
*
|
2007-06-08 |
2013-07-31 |
Genentech, Inc. |
Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
US20090148447A1
(en)
*
|
2007-07-06 |
2009-06-11 |
Trubion Pharmaceuticals, Inc. |
Binding Peptides Having a C-terminally Disposed Specific Binding Domain
|
US9283276B2
(en)
|
2007-08-14 |
2016-03-15 |
Ludwig Institute For Cancer Research Ltd. |
Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
|
WO2009026496A1
(en)
*
|
2007-08-22 |
2009-02-26 |
University Of Southern California |
Grp78 and tumor angiogenesis
|
DK2682400T5
(da)
|
2007-08-28 |
2017-11-27 |
Uab Research Foundation |
Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
EP2268664B1
(en)
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1 compositions and methods for treating cancer
|
AU2008343085B2
(en)
|
2007-12-20 |
2015-03-12 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
ES2518415T3
(es)
|
2007-12-21 |
2014-11-05 |
Medimmune Limited |
Elementos de unión para receptor alfa de interleucina-4 (IL-4Ralfa)
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2252631B1
(en)
|
2008-04-02 |
2016-04-13 |
MacroGenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
ES2587937T3
(es)
|
2008-04-02 |
2016-10-27 |
Macrogenics, Inc. |
Anticuerpos específicos para HER2/neu y métodos para utilizar los mismos
|
CN102099377A
(zh)
|
2008-04-11 |
2011-06-15 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
US9146238B2
(en)
|
2008-04-16 |
2015-09-29 |
The Johns Hopkins University |
Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
|
EP2300032A4
(en)
|
2008-05-13 |
2012-12-05 |
Univ Kansas |
MARKER PRESENTING IN THE FORM OF A MAP PEPTIDE (METAL ABSTRACTION PEPTIDE) AND ASSOCIATED METHODS
|
ES2675730T3
(es)
*
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010019120A1
(en)
|
2008-08-15 |
2010-02-18 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health |
S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
CN102232084B
(zh)
*
|
2008-11-28 |
2014-05-28 |
上海泽生科技开发有限公司 |
纽兰格林及其用途
|
EP2370080A1
(en)
|
2008-12-02 |
2011-10-05 |
University of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
JP2012523463A
(ja)
*
|
2009-04-13 |
2012-10-04 |
ノースウエスタン ユニバーシティ |
軟骨再生のための新規なペプチドベースの足場およびその使用方法
|
SG10201507044PA
(en)
|
2009-05-29 |
2015-10-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
RU2583298C2
(ru)
|
2009-10-07 |
2016-05-10 |
Макродженикс, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US20110081293A1
(en)
|
2009-10-07 |
2011-04-07 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding lipid compounds
|
US9175075B2
(en)
|
2009-12-08 |
2015-11-03 |
AbbVie Deutschland GmbH & Co. KG |
Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
|
US8912136B2
(en)
|
2009-12-18 |
2014-12-16 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding compounds
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
KR20130000384A
(ko)
|
2010-02-18 |
2013-01-02 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴레귤린 길항제 및 암의 치료에서의 그의 용도
|
US20110207789A1
(en)
|
2010-02-19 |
2011-08-25 |
Ye Fang |
Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
|
PE20170779A1
(es)
|
2010-03-04 |
2017-07-04 |
Macrogenics Inc |
Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2575880B1
(en)
|
2010-05-27 |
2019-01-16 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
CN103154035B
(zh)
|
2010-05-27 |
2017-05-10 |
根马布股份公司 |
针对her2的单克隆抗体
|
ES2717908T3
(es)
|
2010-06-14 |
2019-06-26 |
Lykera Biomed S A |
Anticuerpos S100A4 y usos terapéuticos de los mismos
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
ES2634098T3
(es)
|
2011-01-14 |
2017-09-26 |
The Regents Of The University Of California |
Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
|
EP2500033A1
(en)
*
|
2011-03-17 |
2012-09-19 |
Institut Pasteur |
Method for preparing muliple antigen glycopeptide carbohydrate conjugates
|
US9051619B2
(en)
|
2011-03-25 |
2015-06-09 |
Florida Agricultural and Mechanical University (FAMU) |
Methods and compositions for prostate cancer metastasis
|
EP2699598B1
(en)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
EP2744824A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Neuregulin antibodies and uses thereof
|
JP6356605B2
(ja)
*
|
2011-10-19 |
2018-07-11 |
ロシュ グリクアート アーゲー |
フコシル化抗体の分離法
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
BR112014012979A2
(pt)
|
2011-11-30 |
2020-10-20 |
Genentech, Inc. |
mutações erbb3 em câncer
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
MX357708B
(es)
|
2011-12-14 |
2018-07-20 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
SG10202006762PA
(en)
|
2012-01-27 |
2020-08-28 |
Abbvie Deutschland |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
WO2013177593A2
(en)
|
2012-05-25 |
2013-11-28 |
Phosimmune, Inc. |
Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
|
US9187735B2
(en)
|
2012-06-01 |
2015-11-17 |
University Of Kansas |
Metal abstraction peptide with superoxide dismutase activity
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
EP2897631A4
(en)
|
2012-08-31 |
2016-10-05 |
Univ Virginia Patent Found |
TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSIS
|
AU2013312529A1
(en)
|
2012-09-05 |
2015-04-16 |
The University Of Birmingham |
Target peptides for colorectal cancer therapy and diagnostics
|
US9381244B2
(en)
|
2012-09-07 |
2016-07-05 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
TWI675044B
(zh)
*
|
2012-11-14 |
2019-10-21 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
KR20150127720A
(ko)
|
2013-03-14 |
2015-11-17 |
유니버시티 오브 매릴랜드, 발티모어 |
안드로겐 수용체 하향 조절제 및 그의 용도
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
BR112016002970A2
(pt)
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
WO2015034519A1
(en)
*
|
2013-09-03 |
2015-03-12 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
EP4043493A1
(en)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
WO2015160928A2
(en)
|
2014-04-15 |
2015-10-22 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
KR102223502B1
(ko)
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
US10774387B2
(en)
|
2014-05-19 |
2020-09-15 |
The Johns Hopkins University |
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
|
EA037006B1
(ru)
|
2014-06-06 |
2021-01-26 |
Бристол-Майерс Сквибб Компани |
Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
|
AU2015274504B2
(en)
|
2014-06-11 |
2021-02-04 |
Kathy A. Green |
Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
|
CA2954475C
(en)
|
2014-07-31 |
2023-05-16 |
Uab Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
CA2959336A1
(en)
|
2014-08-25 |
2016-03-03 |
The Johns Hopkins University |
Methods and compositions related to prostate cancer therapeutics
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
PL3221363T3
(pl)
|
2014-11-21 |
2021-01-11 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko cd73 i ich zastosowanie
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
PL3240801T3
(pl)
|
2014-12-31 |
2021-06-14 |
Checkmate Pharmaceuticals, Inc. |
Skojarzona immunoterapia nowotworów
|
CN110658340B
(zh)
*
|
2015-01-08 |
2023-10-31 |
苏州康宁杰瑞生物科技有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
DK3653221T3
(da)
|
2015-02-19 |
2022-10-24 |
Compugen Ltd |
Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
RS63897B1
(sr)
|
2015-05-29 |
2023-02-28 |
Bristol Myers Squibb Co |
Antitela protiv ox40 i njihova primena
|
JP7026509B2
(ja)
|
2015-06-24 |
2022-02-28 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista抗体およびフラグメント
|
EA201890162A1
(ru)
|
2015-06-29 |
2018-07-31 |
Бристол-Маерс Сквибб Компани |
Антитела к cd40 с повышенной агонистической активностью
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
RU2638457C2
(ru)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-02-01 |
Amgen Inc. |
ASGR inhibitors
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
EP3377532B1
(en)
|
2015-11-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA3008392C
(en)
|
2015-12-17 |
2021-11-09 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
JP2019509993A
(ja)
|
2016-02-12 |
2019-04-11 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista(b7h5)抗体
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN116063494A
(zh)
|
2016-03-04 |
2023-05-05 |
洛克菲勒大学 |
具有增强的激动剂活性的cd40的抗体
|
BR112018067368A2
(pt)
|
2016-03-04 |
2019-01-15 |
Bristol-Myers Squibb Company |
terapia de combinação com anticorpos anti-cd73
|
EP3432927A4
(en)
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
EA201892260A1
(ru)
|
2016-04-07 |
2019-03-29 |
Дзе Джонс Хопкинс Юниверсити |
Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
|
UA125382C2
(uk)
|
2016-04-15 |
2022-03-02 |
Імьюнекст Інк. |
Антитіла проти людського vista та їх застосування
|
JP7002467B2
(ja)
|
2016-04-15 |
2022-01-20 |
マクロジェニクス,インコーポレーテッド |
新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法
|
AU2017252527A1
(en)
|
2016-04-18 |
2018-11-08 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
WO2017184553A1
(en)
*
|
2016-04-18 |
2017-10-26 |
Baylor College Of Medicine |
Cancer gene therapy targeting cd47
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
WO2018009505A1
(en)
|
2016-07-08 |
2018-01-11 |
Bristol-Myers Squibb Company |
1,3-dihydroxy-phenyl derivatives useful as immunomodulators
|
UY37325A
(es)
|
2016-07-14 |
2018-01-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
CA3036714A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing uch-l1 status in patient samples
|
JP7239179B2
(ja)
|
2016-10-05 |
2023-03-14 |
ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション,インコーポレイテッド |
Nk細胞および抗pdl1による癌治療法に関連する方法および組成物
|
US10988507B2
(en)
|
2016-11-07 |
2021-04-27 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP7106572B2
(ja)
|
2016-12-20 |
2022-07-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な化合物
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
WO2018128939A1
(en)
|
2017-01-05 |
2018-07-12 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
US11377497B2
(en)
|
2017-01-23 |
2022-07-05 |
Suzhou Alphamab Co., Ltd. |
PD-L1 binding polypeptide or composite
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
JP7150745B2
(ja)
|
2017-03-27 |
2022-10-11 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤としての置換イソキノリン誘導体
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
BR112019021612A2
(pt)
|
2017-04-15 |
2020-05-12 |
Abbott Laboratories |
Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
EP3635407A1
(en)
|
2017-04-28 |
2020-04-15 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
CA3078725A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
CN110720041B
(zh)
|
2017-05-30 |
2024-04-26 |
雅培实验室 |
用心肌肌钙蛋白i和早期生物标记物帮助诊断和评价人受试者中轻度创伤性脑损伤的方法
|
JP7206222B2
(ja)
|
2017-06-23 |
2023-01-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
Pd-1のアンタゴニストとして作用する免疫調節剤
|
CA3068041A1
(en)
|
2017-07-03 |
2019-01-10 |
Abbott Laboratories |
Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
US11492375B2
(en)
|
2017-10-03 |
2022-11-08 |
Bristol-Myers Squibb Company |
Cyclic peptide immunomodulators
|
JP2021501801A
(ja)
|
2017-11-01 |
2021-01-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の処置に用いるための免疫刺激アゴニスト抗体
|
AU2018378971A1
(en)
|
2017-12-09 |
2020-01-02 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
|
AU2018378084A1
(en)
|
2017-12-09 |
2020-05-14 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
CN111788227A
(zh)
|
2017-12-27 |
2020-10-16 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
CN111868061A
(zh)
|
2018-01-23 |
2020-10-30 |
百时美施贵宝公司 |
用作免疫调节剂的2,8-二酰基-2,8-二氮杂螺[5.5]十一烷化合物
|
JP7326306B2
(ja)
|
2018-03-01 |
2023-08-15 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な化合物
|
AU2019236865A1
(en)
|
2018-03-23 |
2020-10-01 |
Bristol-Myers Squibb Company |
Antibodies against MICA and/or MICB and uses thereof
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
WO2019200256A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
CA3104664A1
(en)
|
2018-06-29 |
2020-01-02 |
North Carolina State University |
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
|
WO2020006516A1
(en)
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
TW202028244A
(zh)
|
2018-10-09 |
2020-08-01 |
美商建南德克公司 |
用於確定突觸形成之方法及系統
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
WO2020115223A1
(en)
|
2018-12-05 |
2020-06-11 |
Katholieke Universiteit Leuven |
S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
|
CN109929037B
(zh)
|
2019-04-01 |
2023-03-17 |
华博生物医药技术(上海)有限公司 |
针对程序性死亡配体的结合物及其应用
|
KR20220044490A
(ko)
|
2019-06-21 |
2022-04-08 |
백시넥스 인코포레이티드 |
세마포린-4d 차단(sema4d) 및 dc1 요법을 사용한 조합 요법
|
US10851157B2
(en)
|
2019-07-01 |
2020-12-01 |
Gensun Biopharma, Inc. |
Antagonists targeting the TGF-β pathway
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
KR20220079893A
(ko)
|
2019-10-04 |
2022-06-14 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 화합물
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
CN115443171A
(zh)
|
2020-05-08 |
2022-12-06 |
诺沃库勒有限责任公司 |
向多能干细胞施加交变电场的组合物和方法
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
US20220043000A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Methods and kits for detecting sars-cov-2 protein in a sample
|
WO2022029494A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Rapid Diagnostics International Unlimited Company |
Assays for detecting sars-cov-2
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
WO2022235754A1
(en)
|
2021-05-05 |
2022-11-10 |
Bristol-Myers Squibb Company |
Lactone and lactam containing compounds useful as immunomodulators
|
EP4341699A1
(en)
|
2021-05-18 |
2024-03-27 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
CN117425666A
(zh)
|
2021-06-09 |
2024-01-19 |
百时美施贵宝公司 |
环肽免疫调节剂
|
AU2022293389A1
(en)
|
2021-06-14 |
2024-01-04 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2023283523A1
(en)
|
2021-07-06 |
2023-01-12 |
Bristol-Myers Squibb Company |
2,3-dihydrobenzo[b][l,4]dioxin-6-yl containing compounds useful as immunomodulators
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|